Interest Expense is the amount reported by a company or individual as an expense for borrowed money. EyePoint's interest expense for the
three
months ended in Mar. 2026 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.03 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. EyePoint's Operating Income for the
three
months ended in Mar. 2026 was $ -87.23 Mil. EyePoint's Interest Expense for the
three
months ended in Mar. 2026 was $ 0.00 Mil.
GuruFocus does not calculate EyePoint's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
EyePoint (NAS:EYPT) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
EyePoint's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
GuruFocus does not calculate EyePoint's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
EyePoint Interest Expense Historical Data
* Premium members only.
The historical data trend for EyePoint's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EyePoint (EYPT) has a Interest Expense of $-0.03 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on EyePoint and its competitors.
Is EyePoint's Interest Expense too high?
EyePoint's current Interest Expense is $-0.03 Mil. Overall, EyePoint has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EyePoint's Interest Expense compare to SPTX and CRVS?
EyePoint's Interest Expense of $-0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on EyePoint and its competitors. EyePoint's current Interest Expense is $-0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EyePoint stock overvalued right now?
Based on GuruFocus' analysis, EyePoint (EYPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.80, compared to a current price of $13.98 — trading 1647.5% above its estimated fair value. The current Interest Expense is $-0.03 Mil. EyePoint's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For EyePoint (EYPT), the current Interest Expense is $-0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EyePoint (EYPT) Overvalued in 2026?
Based on GuruFocus' analysis, EyePoint stock appears to be overvalued.
The current stock price of $13.98 is trading 1647.5% above its estimated GF Value™ of $0.80.
GuruFocus considers EyePoint to be Significantly Overvalued.
Key valuation signals for EYPT:
Interest Expense: $-0.03 Mil
GF Value™: $0.80 vs. price of $13.98 (1647.5% above fair value)
No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
34GF Score
Get the complete analysis for EYPT
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EYPT has been successfully added to your 
